Managers / Q1 2019 · view latest →
HARBOURVEST PARTNERS LLC
CIK 0001201001 · ONE LINCOLN STREET, SUITE 1700, BOSTON, MA, 02111 · 617-348-3707
Summary
Harbourvest Partners LLC reported $283M in U.S.-listed holdings across 33 positions for Q1 2019.
The portfolio is heavily concentrated: Solarwinds alone accounts for 57.5% of reported value.
Compared with Q4 2018, the fund opened 12 new positions and exited 11.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 92.4% · $261M
- Other · 7.6% · $21M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2018 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| KLDOKaliedo Biosciences, Inc. | NEW | +1.17M | 1.17M | +$17M | $17M |
| Smartsheet, Inc. | NEW | +225.8K | 225.8K | +$9M | $9M |
| TPI Composites, Inc. | NEW | +80.1K | 80.1K | +$2M | $2M |
| NeoPhotonics Corp. | NEW | +311.8K | 311.8K | +$2M | $2M |
| Antero Resources LLC | NEW | +171.2K | 171.2K | +$2M | $2M |
| RYTMRhythm Pharmaceuticals, Inc. | NEW | +50.2K | 50.2K | +$1M | $1M |
| EYENational Vision, Inc. | NEW | +25.2K | 25.2K | +$792,000 | $792,000 |
| Audentes Therapeutics, Inc. | NEW | +18.2K | 18.2K | +$710,000 | $710,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | Solarwinds Corp. | Common | 57.53% | $163M | 8.33M |
| 2 | Rubius Therapeutics, Inc. | Common | 6.32% | $18M | 986.9K |
| 3 | KLDOKaliedo Biosciences, Inc.history → | Common | 5.99% | $17M | 1.17M |
| 4 | Evelo Biosciences, Inc. | Common | 4.99% | $14M | 1.76M |
| 5 | Finjan Holdings, Inc. | Common | 4.46% | $13M | 4.30M |
| 6 | SNAPSnap, Inc.history → | Common | 3.94% | $11M | 1.01M |
| 7 | Smartsheet, Inc. | Common | 3.26% | $9M | 225.8K |
| 8 | LendingClub Corp. | Common | 2.71% | $8M | 2.48M |
| 9 | Zuora, Inc. | Common | 1.32% | $4M | 185.6K |
| 10 | INOVInovalon Holdings, Inc.history → | Common | 1.00% | $3M | 227.6K |
| 11 | YEXTYext, Inc. | Common | 0.89% | $3M | 115.1K |
| 12 | Carbon Black, Inc. | Common | 0.85% | $2M | 172.3K |
| 13 | TPI Composites, Inc. | Common | 0.81% | $2M | 80.1K |
| 14 | NeoPhotonics Corp. | Common | 0.69% | $2M | 311.8K |
| 15 | SFIXStitchfix, Inc. | Common | 0.67% | $2M | 66.6K |
| 16 | Antero Resources LLC | Common | 0.54% | $2M | 171.2K |
| 17 | U.S. Auto Parts Network, Inc. | Common | 0.53% | $1M | 1.48M |
| 18 | DOCUDocusign, Inc. | Common | 0.53% | $1M | 28.7K |
| 19 | RYTMRhythm Pharmaceuticals, Inc. | Common | 0.49% | $1M | 50.2K |
| 20 | Castlight Health, Inc. | Common | 0.46% | $1M | 349.1K |
| 21 | CTMXCytomx Therapeutics, Inc. | Common | 0.30% | $851,000 | 79.2K |
| 22 | Kala Pharmaceuticals, Inc. | Common | 0.29% | $820,000 | 99.2K |
| 23 | EYENational Vision, Inc. | Common | 0.28% | $792,000 | 25.2K |
| 24 | Audentes Therapeutics, Inc. | Common | 0.25% | $710,000 | 18.2K |
| 25 | Mimecast Ltd. | Ordinary | 0.20% | $566,000 | 11.9K |
| 26 | Proteostasis Therapeutics, Inc. | Common | 0.20% | $555,000 | 440.6K |
| 27 | Revance Therapeutics, Inc. | Common | 0.15% | $419,000 | 26.6K |
| 28 | Trevena, Inc. | Common | 0.13% | $365,000 | 233.8K |
| 29 | INSPInspire Medical Systems, Inc. | Common | 0.13% | $354,000 | 6.2K |
| 30 | Ramaco Resources, Inc. | Common | 0.04% | $121,000 | 20.8K |
| 31 | HNRGHallador Energy Resources, Inc. | Common | 0.03% | $91,000 | 17.4K |
| 32 | YUMA Energy, Inc. | Common | 0.01% | $38,000 | 322.5K |
| 33 | AKAOQAchaogen, Inc. | Common | 0.00% | $9,000 | 20.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $101M | 5 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $174M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $205M | 9 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $91M | 15 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $154M | 16 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $203M | 22 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $192M | 34 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $188M | 40 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $219M | 48 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $299M | 53 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $295M | 58 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $352M | 60 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $297M | 63 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $299M | 65 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $306M | 67 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $305M | 62 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $490M | 66 | May 26, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2021 | $782M | 67 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.1B | 56 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.0B | 51 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $746M | 44 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $256M | 26 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $270M | 36 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $232M | 28 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $207M | 36 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $243M | 35 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $240M | 33 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $262M | 32 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $283M | 33 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $211M | 32 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.